Showing results (11-20 of 173) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|November 9, 2022
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survivalNaseema Gangat, Kebede H Begna, Aref Al-Kali, et al.
American Journal of Hematology|May 6, 2017
Outcome of elderly patients after failure to hypomethylating agents given as frontline therapy for acute myeloid leukemia: Single institution experienceRama Nanah, Kristen McCullough, William Hogan, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 21, 2015
Patients With Therapy-Related CMML Have Shorter Median Overall Survival Than Those With De Novo CMML: Mayo Clinic Long-Term Follow-Up ExperienceSalih Subari, Mrinal Patnaik, Dima Alfakara, et al.
Oncotarget|July 13, 2014
A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesisNa Shen, Fei Yan, Jiuxia Pang, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 17, 2014
Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experienceAysha Alsahlawi, Hassan Alkhateeb, Mrinal Patnaik, et al.
International Journal of Hematology|January 20, 2016
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapySalih Subari, Firas Baidoun, Muhanad Hreh, et al.
ACS Applied Materials & Interfaces|April 19, 2018
HDL-AuNPs-BMS Nanoparticle Conjugates as Molecularly Targeted Therapy for LeukemiaNa Shen, Fei Yan, Jiuxia Pang, et al.
Anticancer Research|July 5, 2020
Phase 1b Study of IGF-Methotrexate Conjugate in the Treatment of High-grade Myelodysplastic SyndromesHassan B Alkhateeb, Mrinal M Patnaik, Aref Al-Kali, et al.
Leukemia & Lymphoma|October 15, 2019
Clinical outcome of patients diagnosed with myelodysplastic syndrome-unclassifiable (MDS-U): single center experienceFiras Baidoun, Dong Chen, Mrinal Patnaik, et al.
British Journal of Haematology|December 17, 2014
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosisRamy A Abdelrahman, Kebede H Begna, Aref Al-Kali, et al.
Pageof 18